Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, enabling EirGenix to offer continuous perfusion and integrated hybrid continuous purification to clients. Transcenta will receive upfront and milestone payments plus royalties and retain rights to reinvest proceeds into its R&D pipeline. Transcenta CEO Xueming Qian framed the deal as a lever to expand global access and affordability of biologics. The agreement illustrates growing commercial traction for continuous manufacturing IP and the role of CDMOs in scaling next‑generation biologics production.